BACKGROUND. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5 alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. METHODS. In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. RESULTS. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P less than 0.001), an increase of 1.6 ml per second (22 percent, P less than 0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P less than 0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups. CONCLUSIONS. The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
Source Information
Merck Research Laboratories, Rahway, NJ 07065.
This article has been cited by other articles:
Canguven, O., Burnett, A. L.
(2008). The Effect of 5 {alpha}-Reductase Inhibitors on Erectile Function. J Androl
29: 514-523
[Abstract][Full Text]
Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson, K. M., Daifotis, A. G., Gann, P. H.
(2007). Detection Bias Due to the Effect of Finasteride on Prostate Volume: A Modeling Approach for Analysis of the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst
99: 1366-1374
[Abstract][Full Text]
Moinpour, C. M., Darke, A. K., Donaldson, G. W., Thompson, I. M. Jr, Langley, C., Ankerst, D. P., Patrick, D. L., Ware, J. E. Jr, Ganz, P. A., Shumaker, S. A., Lippman, S. M., Coltman, C. A. Jr
(2007). Longitudinal Analysis of Sexual Function Reported by Men in the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst
99: 1025-1035
[Abstract][Full Text]
Amory, J. K., Wang, C., Swerdloff, R. S., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., Walker, S. E., Haberer, L. J., Clark, R. V.
(2007). The Effect of 5{alpha}-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. J. Clin. Endocrinol. Metab.
92: 1659-1665
[Abstract][Full Text]
Kleinberg, D. L., Ruan, W., Yee, D., Kovacs, K. T., Vidal, S.
(2007). Insulin-Like Growth Factor (IGF)-I Controls Prostate Fibromuscular Development: IGF-I Inhibition Prevents Both Fibromuscular and Glandular Development in Eugonadal Mice. Endocrinology
148: 1080-1088
[Abstract][Full Text]
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Montori, V. M.
(2006). Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab.
91: 1995-2010
[Abstract][Full Text]
Talcott, J. A.
(2005). Rebalancing Ratios and Improving Impressions: Later Thoughts From the Prostate Cancer Prevention Trial Investigators. JCO
23: 7388-7390
[Full Text]
Soletormos, G., Semjonow, A., Sibley, P. E.C., Lamerz, R., Petersen, P. H., Albrecht, W., Bialk, P., Gion, M., Junker, F., Schmid, H.-P., Van Poppel, H., on behalf of the European Group on Tumor Markers,
(2005). Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice. Clin. Chem.
51: 1342-1351
[Abstract][Full Text]
Gould, A L.
(2005). Bayesian analysis of multicentre trial outcomes. Stat Methods Med Res
14: 249-280
[Abstract]
Henderson, N. A., Robaire, B.
(2005). Effects of PNU157706, a Dual 5{alpha}-Reductase Inhibitor, on Rat Epididymal Sperm Maturation and Fertility. Biol. Reprod.
72: 436-443
[Abstract][Full Text]
Parnes, H. L., Thompson, I. M., Ford, L. G.
(2005). Prevention of Hormone-Related Cancers: Prostate Cancer. JCO
23: 368-377
[Abstract][Full Text]
Rosner, W.
(2004). Proscar and Propecia--A Therapeutic Perspective. J. Clin. Endocrinol. Metab.
89: 3096-3098
[Full Text]
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L. Jr., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M. Jr., Clarke, H. S., Crawford, E. D., Diokno, A., Foley, J. P., Foster, H. E., Jacobs, S. C., Kaplan, S. A., Kreder, K. J., Lieber, M. M., Lucia, M. S., Miller, G. J., Menon, M., Milam, D. F., Ramsdell, J. W., Schenkman, N. S., Slawin, K. M., Smith, J. A., the Medical Therapy of Prostatic Symptoms (MTOPS),
(2003). The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. NEJM
349: 2387-2398
[Abstract][Full Text]
Vaughan, E. D. Jr.
(2003). Medical Management of Benign Prostatic Hyperplasia -- Are Two Drugs Better Than One?. NEJM
349: 2449-2451
[Full Text]
Bhasin, S., Singh, A. B., Mac, R. P., Carter, B., Lee, M. I., Cunningham, G. R.
(2003). Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan. J Androl
24: 299-311
[Full Text]
Gelmann, E. P.
(2002). Molecular Biology of the Androgen Receptor. JCO
20: 3001-3015
[Abstract][Full Text]
Giles, G. G., Severi, G., Sinclair, R., English, D. R., McCredie, M. R. E., Johnson, W., Boyle, P., Hopper, J. L.
(2002). Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study. Cancer Epidemiol. Biomarkers Prev.
11: 549-553
[Abstract][Full Text]
Suzuki, S., Platz, E. A, Kawachi, I., Willett, W. C, Giovannucci, E.
(2002). Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am. J. Clin. Nutr.
75: 689-697
[Abstract][Full Text]
Kunelius, P., Lukkarinen, O., Hannuksela, M. L., Itkonen, O., Tapanainen, J. S.
(2002). The Effects of Transdermal Dihydrotestosterone in the Aging Male: A Prospective, Randomized, Double Blind Study. J. Clin. Endocrinol. Metab.
87: 1467-1472
[Abstract][Full Text]
Matsumoto, A. M.
(2002). Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men. J. Gerontol. A Biol. Sci. Med. Sci.
57: M76-99
[Full Text]
Dixon, S. C., Knopf, K. B., Figg, W. D.
(2001). The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents. Pharmacol. Rev.
53: 73-92
[Abstract][Full Text]
Phanjoo, A. L.
(2000). Sexual dysfunction in old age. Adv. Psychiatr. Treat.
6: 270-277
[Full Text]
Moinpour, C. M., Lovato, L. C., Thompson, I. M. Jr, Ware, J. E. Jr, Ganz, P. A., Patrick, D. L., Shumaker, S. A., Donaldson, G. W., Ryan, A., Coltman, C. A. Jr
(2000). Profile of Men Randomized to the Prostate Cancer Prevention Trial: Baseline Health-Related Quality of Life, Urinary and Sexual Functioning, and Health Behaviors. JCO
18: 1942-1953
[Abstract][Full Text]
Marcelli, M., Cunningham, G. R.
(1999). Hormonal Signaling in Prostatic Hyperplasia and Neoplasia. J. Clin. Endocrinol. Metab.
84: 3463-3468
[Full Text]
Anderson, R. A., Martin, C. W., Kung, A. W. C., Everington, D., Pun, T. C., Tan, K. C. B., Bancroft, J., Sundaram, K., Moo-Young, A. J., Baird, D. T.
(1999). 7{alpha}-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men. J. Clin. Endocrinol. Metab.
84: 3556-3562
[Abstract][Full Text]
Price, V. H.
(1999). Treatment of Hair Loss. NEJM
341: 964-973
[Full Text]
Fukuta, Y., Fukuda, Y., Higashino, R., Yoshida, K., Ogishima, M., Tamaki, H., Takei, M.
(1999). Z-350, A Novel Compound with alpha 1-Adrenoceptor Antagonistic and Steroid 5alpha -Reductase Inhibitory Actions: Pharmacological Properties In Vivo. J. Pharmacol. Exp. Ther.
290: 1013-1018
[Abstract][Full Text]
Scher, H. I., Kelly, W. M. K., Zhang, Z.-F., Ouyang, P., Sun, M., Schwartz, M., Ding, C., Wang, W., Horak, I. D., Kremer, A. B.
(1999). Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer. JNCI J Natl Cancer Inst
91: 244-251
[Abstract][Full Text]
Cummings, D. E., Kumar, N., Bardin, C. W., Sundaram, K., Bremner, W. J.
(1998). Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception. J. Clin. Endocrinol. Metab.
83: 4212-4219
[Abstract][Full Text]
Vashi, V., Chung, M., Hilbert, J., Lawrence, V., Phillips, K.
(1998). Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin. J Clin Pharmacol
38: 1072-1076
[Abstract]
Lopez-Otin, C., Diamandis, E. P.
(1998). Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features. Endocr. Rev.
19: 365-396
[Abstract][Full Text]
Katashima, M., Yamamoto, K., Tokuma, Y., Hata, T., Sawada, Y., Iga, T.
(1998). Pharmacokinetic and Pharmacodynamic Study of a New Nonsteroidal 5alpha -Reductase Inhibitor, 4-[3-[3-[Bis(4-Isobutylphenyl)Methylamino]Benzoyl]-1H-Indol-1-yl]-Butyric Acid, in Rats. J. Pharmacol. Exp. Ther.
284: 914-920
[Abstract][Full Text]
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., Waldstreicher, J., The Finasteride Long-Term Efficacy and Safety Stud,
(1998). The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia. NEJM
338: 557-563
[Abstract][Full Text]
Bjelfman, C., Soderstrom, T. G., Brekkan, E., Norlen, B. J., Egevad, L., Unge, T., Andersson, S., Rane, A.
(1997). Differential Gene Expression of Steroid 5{alpha}-Reductase 2 in Core Needle Biopsies from Malignant and Benign Prostatic Tissue. J. Clin. Endocrinol. Metab.
82: 2210-2214
[Abstract][Full Text]
Schwartz, J. I., Tanaka, W. K., Wang, D. Z., Ebel, D. L., Geissler, L. A., Dallob, A., Hafkin, B., Gertz, B. J.
(1997). MK-386, an Inhibitor of 5{alpha}-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen. J. Clin. Endocrinol. Metab.
82: 1373-1377
[Abstract][Full Text]
Padayatty, S. J., Marcelli, M., Shao, T. C., Cunningham, G. R.
(1997). Lovastatin-Induced Apoptosis in Prostate Stromal Cells. J. Clin. Endocrinol. Metab.
82: 1434-1439
[Abstract][Full Text]
Farmer, A., Noble, J.
(1997). Drug treatment for benign prostatic hyperplasia. BMJ
314: 1215-1215
[Full Text]
George, F. W.
(1997). Androgen Metabolism in the Prostate of the Finasteride-Treated, Adult Rat: A Possible Explanation for the Differential Action of Testosterone and 5{alpha}-Dihydrotestosterone during Development of the Male Urogenital Tract. Endocrinology
138: 871-877
[Abstract][Full Text]
Kuchel, G. A., DuBeau, C. E., Resnick, N. M., Thien, T., Lenders, J. W.M., Lepor, H.
(1997). Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia. NEJM
336: 293-294
[Full Text]
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., Padley, R. J., The Veterans Affairs Cooperative Studies Benign Pr,
(1996). The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia. NEJM
335: 533-540
[Abstract][Full Text]
Walsh, P. C.
(1996). Treatment of Benign Prostatic Hyperplasia. NEJM
335: 586-587
[Full Text]
Oesterling, J. E.
(1995). Benign Prostatic Hyperplasia -- Medical and Minimally Invasive Treatment Options. NEJM
332: 99-110
[Full Text]
Kirby, R S
(1994). Controversies in Management: Urologists must grasp the future. BMJ
309: 716-717
[Full Text]
Rittmaster, R. S.
(1994). Finasteride. NEJM
330: 120-125
[Full Text]
Geller, D. M., DuBeau, C. E., Blumenstein, B. A., Gormley, G. J., Stoner, E., Slater, E. E.
(1993). Finasteride for Benign Prostatic Hyperplasia. NEJM
328: 442-443
[Full Text]
